Is the price fair?
What GILD's price assumes
Today's price asks for −1.3% free cash flow growth a year; over the last three years Gilead Sciences delivered 13%, less than the record.
5.84
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 8.4%
Free cash flow yield · Drug Manufacturers - General median 5.8%
- Growth the price implies
- −1.3%
Growth the price implies · The price pays for −1.3% free cash flow growth a year for a decade; the business has delivered +13% a year over the last three.
- Price / book
- 7.38
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 7.38
- EV / EBIToperating margin −8.2%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 6.33
- Free cash flow, trailing twelve months
- $12.9B
- Market capitalisation
- $153.7B
- 3-year revenue growth
- +3.6%
- 3-year free cash flow growth
- +13%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - General
Ranks #6 of 16 by Smart Score